Prospective ICH Q2(R2)-aligned total-error validation of label-free untargeted proteomics for host cell protein quantification in biotherapeutics
Khalil, S.; Dierick, J.-F.; Bourguignon, P.; Plisnier, M.
Show abstract
Untargeted proteomics enables quantitative determination of host cell proteins (HCPs) in biotherapeutics, yet no workflow has been validated under ICH Q2(R2) for regulated quality control. We report a prospective validation of label-free untargeted proteomics for HCP quantification using a total-error (TE) approach. A stable isotope-labeled whole-proteome standard was spiked into NISTmAb at seven levels (20-80 ng). Four independent assays (198 injections) supported hierarchical replication and one-way random-effects ANOVA variance decomposition with Welch-Satterthwaite adjustment. Dual entrapment analysis demonstrated empirical peptide-level false discovery proportions below 1% at q = 0.01. Deterministic parsimony inference ensured invariant protein-group definition. Weighted least-squares regression (R{superscript 2} = 0.993) identified stable proportional compression with recoveries of 81-85%. Repeatability dominated the variance structure (median CV 2.7%); intermediate precision total SD ranged from 0.69% to 3.81% over the validated range. Accuracy profiles integrating empirical bias with a log- log variance model showed 95% {beta}-expectation and 95/95 content tolerance intervals fully contained within {+/-}30%, with a lower limit of quantification (LLOQ) of 20 ng. Abundance-stratified TE analysis revealed concentration-dependent calibration heterogeneity masked by aggregate-level estimation; stratum-specific {beta}-expectation intervals within {+/-}35% defined an abundance-aware LLOQ of 3.6 ppm (P95 = 3.87 ppm). Robustness under independent search software (FragPipe, CCC = 0.998, LoA {+/-}9%) and cross-platform acquisition (Astral, CCC = 0.980, LoA {+/-}18%) remained within predefined {+/-}30% agreement limits. System suitability criteria were derived empirically from validation performance. This is the first prospective ICH Q2(R2)-aligned validation of untargeted proteomics for HCP quantification, with a statistical framework applicable to other high-dimensional analytical methods requiring regulatory qualification. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=113 SRC="FIGDIR/small/710150v1_ufig1.gif" ALT="Figure 1"> View larger version (29K): org.highwire.dtl.DTLVardef@1f5331aorg.highwire.dtl.DTLVardef@ee2234org.highwire.dtl.DTLVardef@798eaorg.highwire.dtl.DTLVardef@c84034_HPS_FORMAT_FIGEXP M_FIG C_FIG
Matching journals
The top 5 journals account for 50% of the predicted probability mass.